Targeting metastatic cancer

K Ganesh, J Massagué - Nature medicine, 2021 - nature.com
Despite recent therapeutic advances in cancer treatment, metastasis remains the principal
cause of cancer death. Recent work has uncovered the unique biology of metastasis …

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and …

M Guckenberger, Y Lievens, AB Bouma… - The Lancet …, 2020 - thelancet.com
Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology

N Abu-Rustum, C Yashar, R Arend, E Barber… - Journal of the National …, 2023 - jnccn.org
Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly
as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the …

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

N Concin, X Matias-Guiu, I Vergote, D Cibula… - International Journal of …, 2021 - ijgc.bmj.com
A European consensus conference on endometrial carcinoma was held in 2014 to produce
multi-disciplinary evidence-based guidelines on selected questions. Given the large body of …

[HTML][HTML] Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial

DA Palma, R Olson, S Harrow, S Gaede… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial

R Phillips, WY Shi, M Deek, N Radwan, SJ Lim… - JAMA …, 2020 - jamanetwork.com
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

[HTML][HTML] Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma

S McBride, E Sherman, CJ Tsai, S Baxi… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE The objective response rate (ORR) for single-agent anti–programmed death
receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and …

[HTML][HTML] Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Y Lievens, M Guckenberger, D Gomez, M Hoyer… - Radiotherapy and …, 2020 - Elsevier
Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019

S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell… - European urology, 2020 - Elsevier
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial

C Tang, P Msaouel, K Hara, H Choi, V Le… - The lancet …, 2021 - thelancet.com
Background The role of radiotherapy in metastatic renal cell carcinoma is controversial. We
prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for …